<SEC-DOCUMENT>0001193125-17-178145.txt : 20170522
<SEC-HEADER>0001193125-17-178145.hdr.sgml : 20170522
<ACCEPTANCE-DATETIME>20170522164733
ACCESSION NUMBER:		0001193125-17-178145
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20170519
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170522
DATE AS OF CHANGE:		20170522

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CareDx, Inc.
		CENTRAL INDEX KEY:			0001217234
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				943316839
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36536
		FILM NUMBER:		17861498

	BUSINESS ADDRESS:	
		STREET 1:		3260 BAYSHORE BOULEVARD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		415-287-2300

	MAIL ADDRESS:	
		STREET 1:		3260 BAYSHORE BOULEVARD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XDx, Inc.
		DATE OF NAME CHANGE:	20071010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXPRESSION DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20030203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d351708d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;19, 2017 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CAREDX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36536</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">94-3316839</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3260 Bayshore Boulevard </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Brisbane, California 94005 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">287-2300</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name, or
Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;22, 2017, CareDx, Inc. (the
&#147;Company&#148;) issued a press release announcing certain preliminary financial results for the quarter ended March&nbsp;31, 2017. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The
preliminary financial information presented in this press release is based on the Company&#146;s current expectations and may be adjusted as a result of, among other things, completion of customary quarterly review procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is intended to be furnished under Item&nbsp;2.02 and Item 9.01
of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities
of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or the Exchange Act, except as shall be expressly set forth by specific reference in such
a filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;3.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;22, 2017, the Company received a written notice (the &#147;Notice&#148;) from the Listing Qualifications Department of The NASDAQ Stock Market LLC (&#147;Nasdaq&#148;) stating that the Company is not in compliance with Nasdaq Listing Rule
5250(c)(1) for continued listing because the Company did not timely file with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended
March&nbsp;31, 2017 (the &#147;Form <FONT STYLE="white-space:nowrap">10-Q&#148;).</FONT> The Notice was issued in accordance with standard Nasdaq procedures and has no immediate effect on the continued listing of the Company&#146;s common stock on
the Nasdaq Global Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notice indicates that the Company has until July&nbsp;21, 2017 to submit a plan to regain compliance with the Nasdaq
continued listing standards. As previously disclosed in the Company&#146;s Notification of Late Filing on Form <FONT STYLE="white-space:nowrap">12b-25</FONT> filed with the SEC on May&nbsp;15, 2017, the Company requires additional time to complete
the disclosures in the Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> The Company intends to file the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> as promptly as possible, and intends to do so prior to July&nbsp;21, 2017. However, if the
Company is still unable to file the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> by July&nbsp;21, 2017, then the Company intends to submit a compliance plan on or prior to that date. If submission of a compliance plan is necessary and Nasdaq
accepts the Company&#146;s compliance plan, Nasdaq can grant an exception of up to 180 calendar days from the Form <FONT STYLE="white-space:nowrap">10-Q&#146;s</FONT> filing due date, or until November&nbsp;13, 2017, to regain compliance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;19, 2017, Douglas Miller resigned as a member of the Board of Directors of the Company, effective immediately.
Mr.&nbsp;Miller&#146;s departure was not as a result of any disagreement with the Company or any matters relating to the Company&#146;s operations, policies or practices. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;22, 2017, the Company issued a press release disclosing the
Company&#146;s receipt of the Notice. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in this Item 7.01, including Exhibit 99.2 hereto, is being furnished and shall not be deemed &#147;filed&#148; for the purposes of
Section&nbsp;18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act or the Exchange Act, except as
shall be expressly set forth by specific reference to such filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cautionary Note Regarding Forward-Looking Statements</I>. This Current Report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the press releases furnished as Exhibits 99.1 and 99.2 hereto contain forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by these statements. Please refer to the note in the press releases under the heading &#147;Forward-Looking Statements&#148; regarding these forward-looking statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibits are being furnished herewith: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May&nbsp;22, 2017 regarding preliminary financial results of CareDx, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May&nbsp;22, 2017 regarding receipt of notice from Listing Qualifications Department of The NASDAQ Stock Market LLC.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: May&nbsp;22, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>CAREDX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Maag, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter Maag, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d351708dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g351708logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>CareDx Reports Preliminary First Quarter 2017 Financial Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BRISBANE, Calif.,&nbsp;May 22, 2017&nbsp;(GLOBE NEWSWIRE) &#151;&nbsp;CareDx, Inc.&nbsp;(Nasdaq:CDNA), a molecular diagnostics company focused on the
discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the first quarter ended&nbsp;March 31, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent highlights:</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Achieved total preliminary revenues for the first quarter of 2017 of&nbsp;$11.4M to $11.6M</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AlloMap<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;preliminary revenues were&nbsp;$7.7M to $7.9M in the quarter, with quarterly US tests volume up by 12% year-over-year </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Olerup<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;preliminary revenues contributed&nbsp;$3.7M in the first quarter </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Attained AlloSure draft local coverage determination (LCD) by Palmetto GBA. AlloSure is the first and only non-invasive test that uses donor derived cell free DNA to measure allograft injury and identify the probability
of active rejection </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Advanced launch readiness at the 2017 American Transplantation Congress </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Presented data showing high correlation with active kidney transplant rejection in a large prospective multi-center study </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Demonstrated AlloSure&#146;s use in monitoring immunosuppressive treatment for patient recovery from active rejection </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Highlighted intended use in clinical setting with numerous patient case studies </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Appointed Michael Bell as Chief Financial Officer effective April&nbsp;21, 2017 and retained top-tier accounting firm to support financial reporting team </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our strong AlloMap volume and revenue growth in the quarter underscores the build out in our core business. In addition, we are thrilled to receive a
draft LCD for AlloSure and we continue to anticipate CMS coverage this year, and with this milestone achieved, we are well on track to make AlloSure available to kidney transplant patients later in 2017,&#148; said Peter Maag, CareDx President and
Chief Executive Officer. &#147;With our new CFO, Michael Bell, on board, we are making significant improvements within our finance organization.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary First Quarter 2017 Financial Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These
financial results for the three months ended March&nbsp;31, 2017 are preliminary and will be updated with the filing of the upcoming Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary revenues for the three months ended March&nbsp;31, 2017 were $11.4 million to $11.6&nbsp;million compared with $6.6 million in the first quarter
of 2016. Preliminary revenues from AlloMap tests for the three months ended March&nbsp;31, 2017, were $7.7 million to $7.9 million compared with $6.5 million in the first quarter of 2016. Preliminary Olerup revenues in the three months ended
March&nbsp;31, 2017, were $3.7 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the first quarter of 2017, preliminary net loss was in the range of $6.8 million to $5.8 million, compared to
net loss of $9.8 million in the first quarter of 2016. Preliminary basic and diluted net loss per share were in the range $0.32 to $0.27 in the first quarter of 2017, compared to basic and diluted net loss per share of $0.81 in the first quarter of
2016. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary cash and cash equivalents was $12.2 million as of March&nbsp;31, 2017, compared with $17.3 million as
of December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Guidance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the
full year 2017, the Company continues to expect revenue to be in the range of $45 million to $50 million, excluding any potential AlloSure revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CareDx </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx, Inc., based in Brisbane,
California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has
commercialized AlloMap<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a gene expression test that aids clinicians in identifying heart transplant recipients. CareDx is also pursuing the development of additional products for
post-transplant monitoring of other solid organs that use a variety of technologies, including next-generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful
transplants by facilitating a better match between a donor and a recipient of stem cells and organs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit:
<U>www.CareDx.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to
our anticipated future financial results, including our guidance for full fiscal 2017 revenue and preliminary financial results for the three months ended March&nbsp;31, 2017, which final results could change materially, and the development,
commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to
numerous risks and uncertainties, including risk associated with successful research, development and planned commercialization of our technologies. These factors, together with those that are described in our filings with the Securities and
Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2016 filed by us with the SEC on April&nbsp;21, 2017. Any of these may cause our actual results, performance or achievements to differ
materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Caroline Corner, Managing Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke Partners, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T: +1 415-314-1725 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E: <U>caroline.corner@westwicke.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d351708dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g351708g0520022248038.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CareDx Announces Receipt of Expected Letter from Nasdaq </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BRISBANE, CA, May</B><B></B><B>&nbsp;22, 2017:</B> CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and
commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that, as expected, on May&nbsp;22, 2017 it received a standard notification letter from The Nasdaq Stock Market LLC
(&#147;Nasdaq&#148;) stating that because the Company did not timely file its Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2017 (the &#147;Form <FONT STYLE="white-space:nowrap">10-Q&#148;),</FONT> the
Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission (the &#147;SEC&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nasdaq provided the Company until July&nbsp;21, 2017 to submit a plan to regain compliance. The Company intends to file the Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> with the SEC as promptly as possible, and intends to do so prior to July&nbsp;21, 2017. However, if the Company is still unable to file the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> by July&nbsp;21,
2017, then the Company intends to submit a compliance plan on or prior to that date. If submission of a compliance plan is necessary and Nasdaq accepts the Company&#146;s compliance plan, Nasdaq can grant an exception of up to 180 calendar days from
the Form <FONT STYLE="white-space:nowrap">10-Q&#146;s</FONT> filing due date, or until November&nbsp;13, 2017, to regain compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notice from
Nasdaq has no immediate effect on the listing of the Company&#146;s common stock on the Nasdaq Global Market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CareDx </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of
clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a gene expression test that aids clinicians in identifying heart transplant patients
with stable graft function who have a low probability of moderate to severe acute cellular rejection (ACR). CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a proprietary next-generation sequencing&#150;based test to detect donor-derived cell-free DNA <FONT STYLE="white-space:nowrap">(dd-cfDNA)</FONT> after transplantation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful
transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a set of HLA typing products used prior to hematopoietic stem cell/bone
marrow transplantation and organ transplantation. <FONT STYLE="white-space:nowrap">XM-ONE</FONT><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is the first standardized test that quickly identifies a patient&#146;s antigens against HLA
Class&nbsp;I, Class&nbsp;II or antibodies against a donor&#146;s endothelium. For more information, please visit: www.CareDx.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to historical information, this press release contains forward-looking statements with respect to the expected timing for the
filing of the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and our ability to regain compliance with the Nasdaq continued listing standards. These forward-looking statements are based upon information that is currently available to us and our
current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including those related to our ability to file the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> before July&nbsp;21, 2017 and our
ability to regain compliance with the Nasdaq continued listing standards. These factors, together with those that are described in our filings with the SEC, including the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
year ended December&nbsp;31, 2016 as filed by us with the SEC, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim
any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Caroline Corner, Managing Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke Partners, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T: +1 415-314-1725 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E: <U>caroline.corner@westwicke.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g351708g0520022248038.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g351708g0520022248038.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% .<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^J&M64FI
M:'?643*LD\#QJ6Z D8YJ_12:NK#C)Q:DNAR'@/PK>^%X+U+R6"0SLA7RB3C&
M>N0/6NOKC?%WB.?^RT7PU>)/?><-R0 2,$P<\<]\5L>$[G4;OPY;3:J'%XQ;
MS Z;3]XXX^F*RIN,7[./0[,3"K4C]8J-7;M;K]QM4445L<04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AY&*;-*D
M$,DTK!8XU+,3V Y->'^-/&"Z]K]I+H5_<I;K"$< E1NW'M]"*RJU535V=6%P
ML\3/EC]YT<^C_P#"MY6UY9?MIF8P>41MQN^;/_CM=WX;U@Z]H5OJ1A\HR[OD
MSG&&(_I3+Z;3XM'M6U2(31$+@,N[YMO7^=<1I^KK9_$%?LDC)I=P1$L/15RH
M' [?-6/,J,DD]'T_4ZVI8NFW)>^NO=+H>GU'//%;0///(D42#<[N<!1ZDU)7
MSE\=_'-U>ZVOA'3Y62WAVFZV'_6.>0I]@"/SKK/*.]N?BU)K&KOH_@C27U>Z
M0X>YD)2!/<GJ16K!H?C^_ DU'Q3;V.>L%C:*=O\ P)LDUH?#WPC:>#O"EI91
M1*+IT$ES)CEY".?P'3\*ZN@#A)_"7B]$+67CFY\SM]HMHW7\@!7%W_CGXB>"
M_$=AI_B*&RO+&ZF6-;M(MH8$^V,'V->WUC>)O#5EXJTG^S[[<JB194=/O(RG
M((H V:*1%V(JY)P,9/>H+B_L[0@7-W!#GIYD@7^= %BBHX;B&YC\R":.5/[R
M,&'Z5)0 455@U*QN;N6U@NX99XANDC1P2H]Z='?6<TY@BNH'F'6-9 6'X4 6
M**:[I&A>1E51U+' %58]7TV:3RXM0M'D_NK,I/Y9H N5X]\2/%?C[P-:IJ"W
M.F3V,LIC4K 0R>@.2<U[#7DO[0W_ "3V'_K]3^34 0>!=9^(WCG0QJ\>M:;9
M6[2,BJUF'8X.#Z5U#Z3\1HQNB\3Z7,1_"^G[<_B#65\!/^27VW_7Q+_Z$:].
MH \IU3QE\0_"*F?6O#MGJ5@G+SV#,& ]2.WY5T7@WXH>'?&A$-G.;>^ R;6?
MAOP]:[-E#*58 J>"".M?,?QJ\'CP;XDL_$.B;K6&[<MB(X\J8<G'H#U_.@#Z
M=HKBOAIXT7Q=X)MM1NY$2ZC8P7&2 "X[_B,'\:Z\W=L!DW$0'^^* )J*8\T4
M:AGD15;H2P --%S;E@HGC))P!O'- $M%<@WQ%TB.YE$P>.TC&3<MT"YP'(_N
MDX /?(]:* )OB+?'3_ .K3*<,\0B'_ R%/Z$UYG\,?#>CZSIUS<ZA/Y<T,@"
M#S N1BO3?B)IDFK>!=3MH03(J"50.^Q@Q_0&OFNSNGM9-N2O/K7!B7:HFU=6
M/<RV#E0E&,N5M[_<>]VOB,7W^C7^QX8CA H]!BDCT"QO[&?4A<-"\+LR*,=@
M"*\_\(>*;/3=8AGU#YK=0P8;=W52!Q]:L>*O$T>O>((HM$,HBF"QK&HV[F)]
M/RK%33C>6K['2\+*-3EA[JWOT]#W2TG%S9P3CI+&K_F,U\=^+W,/Q?U%[K/R
MZGEL_P!W<,?IBOL.R@^RV%O;DY\J)4S] !7@/QX^'UU_:'_"6Z7"TD;J!>(@
MR4(X#_3'!^E>HMCYN5KZ'T(K!E#*<J1D$4M>:?"'XA6GBGPY;Z=<S*FK6<8C
M>-CS(HX##UXZUZ73$%%%8GBKQ/8^$M"GU.^8808CC!^:1NRCWH YOXCZGXRC
M%KI?A'39'DN0?-O<#$(]/K3H_A5H%YI$<>LQ37E^\8\ZYEF9GWD<D'MS2>*/
MBIIGA31M.N+ZUF:_OX1+%9)C<,@=3VZT^U/COQ+9QW+7%EH-M,H941?.FVGH
M<G !H \I^$]U?>'_ (OWOAJ*[EEL,RH4=B1\O(/UKW#QMI+:QX4OH$O;BT=(
MFD62!]IR 3@^U>#_  G@D7XY7RSW#7,L7V@-,XP7(XS7T7K7_("U#_KVD_\
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MEV1O4UT61&1U#(PP589!%,@N([A-\9)7Z5+70<!YCK_P4T6^U#^U-"NY]$U
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D)%: N4?:K'#G+## C].U%% &M%&(84B4DA%"@GKQ1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g351708logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g351708logo.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( $T ZP,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z *>JZE#I&EW&H7"NT4"[F" %B/;)%3.2A%R9K1I.M-4X
M[LH^&_$]EXHM)KBRBGC2)]C"90#G&>,$U%*JJJNC7%86>%DHS:U[&U6IRA0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M3C^)G@F5MJ^)].!_VI@O\Z -VQUO2M3 -AJ=I=?]<9U?^1H O4 % !0 4 %
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M4 >+^/OA?9>%-9TGQ=X;A>&WM[Z$W5HF6"#>/F7N!V(]Z />* "@ H * "@
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M,4DV#);HN3W&2* /(O@MH.O:IH&HZYIWBE;&YNKMDN-]BD[N0 <EF.>=QXH
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MP*I/XC% %>+X7^!X6W)X8L"?]N/</US0!T%CI6EZ0@CL+&ULU/ $,2QY_(4
M&HZ9IVM6CV>HVEO>6^?FBF0. ?H>AH HZ1X.\-Z#,9]*T2RM)C_RTCB ;\^M
M #-8\'^%]8N?MVKZ+8W$Z@ S31#)';)[_C0!8/A_P_=V]NATC3YH+=2L -NC
M+&.X7CC\* &OX3\-LN'\/Z81Z&TC_P * -.VMH+.VCMK6&."",;4CC4*JCT
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M 4 % !0 4 % !0 4 % !0 4 -2-(]VQ%3<=QVC&3ZT .H * "@ H * "@ H
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
